Akti-1/2

CAS: 612847-09-3

Ref. 3D-FA17246

Información del producto

• Nombre: Akti-1/2
• Sinónimos: 1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one, 1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one, 2H-benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-, 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one

Descripción

Akti-1/2 is a potential anticancer agent that inhibits growth and induces apoptosis in cancer cells. Akti-1/2 has been shown to induce autophagy, which is the process by which cells degrade cellular components, leading to increased mitochondrial membrane potential and inhibition of cell death. Akti-1/2 also activates cyclin D2 and MCL-1 protein expression, which are important for cell cycle progression. Akti-1/2 has inhibitory properties against the proliferation of cancer cells in vitro and synergistic effects with chemical inhibitors. This drug may be useful for the treatment of eye disorders such as macular degeneration or retinitis pigmentosa.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 551.64 g/mol
• Fórmula: C₃₄H₂₉N₇O
• Pureza: Min. 95%
• InChI: InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25,38H,14-17,20H2,(H,39,42)
• Clave InChI: InChIKey=IWCQHVUQEFDRIW-UHFFFAOYSA-N
• SMILES: O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3[nH]c4cc5ncnc5cc4nc3-c3ccccc3)cc2)CC1